Monte Rosa Therapeutics Enters Material Definitive Agreement
Ticker: GLUE · Form: 8-K · Filed: May 16, 2024 · CIK: 1826457
| Field | Detail |
|---|---|
| Company | Monte Rosa Therapeutics, Inc. (GLUE) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $4.70, $4.6999, $0, $96.7 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action
TL;DR
Monte Rosa signed a big deal on May 15th, details TBD.
AI Summary
Monte Rosa Therapeutics, Inc. entered into a Material Definitive Agreement on May 15, 2024. The filing does not disclose the specific details of this agreement or any associated financial figures.
Why It Matters
This filing indicates a significant new agreement for Monte Rosa Therapeutics, which could impact its future operations and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its implications.
Key Players & Entities
- Monte Rosa Therapeutics, Inc. (company) — Registrant
- May 15, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Monte Rosa Therapeutics?
The filing states that Monte Rosa Therapeutics, Inc. entered into a Material Definitive Agreement on May 15, 2024, but does not provide specific details about the agreement itself.
When was the Material Definitive Agreement reported?
The earliest event reported, which is the entry into the Material Definitive Agreement, was on May 15, 2024.
What is Monte Rosa Therapeutics' principal executive office address?
Monte Rosa Therapeutics' principal executive offices are located at 321 Harrison Avenue, Suite 900, Boston, MA 02118.
What is Monte Rosa Therapeutics' telephone number?
Monte Rosa Therapeutics' telephone number is (617) 949-2643.
What is the SIC code for Monte Rosa Therapeutics?
The Standard Industrial Classification (SIC) code for Monte Rosa Therapeutics is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 1,709 words · 7 min read · ~6 pages · Grade level 13.6 · Accepted 2024-05-16 16:06:35
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GLUE The Nasdaq
- $4.70 — Stock"), at a public offering price of $4.70 per share, and, in lieu of Common Stock
- $4.6999 — mon Stock at a public offering price of $4.6999 per Pre-Funded Warrant, which represent
- $0 — d to the public in this offering, minus $0.0001, which is the exercise price of ea
- $96.7 million — e by the Company, will be approximately $96.7 million. The Company may receive nominal procee
Filing Documents
- d813909d8k.htm (8-K) — 36KB
- d813909dex11.htm (EX-1.1) — 273KB
- d813909dex41.htm (EX-4.1) — 69KB
- d813909dex51.htm (EX-5.1) — 11KB
- d813909dex991.htm (EX-99.1) — 10KB
- g813909g0513025904999.jpg (GRAPHIC) — 3KB
- g813909g0516084016188.jpg (GRAPHIC) — 4KB
- 0001193125-24-140533.txt ( ) — 642KB
- glue-20240515.xsd (EX-101.SCH) — 3KB
- glue-20240515_lab.xml (EX-101.LAB) — 18KB
- glue-20240515_pre.xml (EX-101.PRE) — 11KB
- d813909d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits 1.1 Underwriting Agreement, dated May 15, 2024, by and between Monte Rosa Therapeutics, Inc. and TD Securities (USA) LLC, as representative of the several underwriters listed on Schedule 1 thereto. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1). 99.1 Press Release issued by Monte Rosa Therapeutics, Inc. dated May 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monte Rosa Therapeutics, Inc. Date: May 16, 2024 By: /s/ Markus Warmuth Markus Warmuth President and Chief Executive Officer